Immediate bisphosphonate use with endocrine therapy reduced recurrence and increased survival in postmenopausal early breast cancer

December 07, 2011

SAN ANTONIO -- The addition of zoledronic acid to adjuvant endocrine therapy increased bone mineral density and reduced the risk for disease recurrence among postmenopausal women with early hormone receptor-positive breast cancer, according to new data from the ZO-FAST trial.

Richard de Boer, M.D., of the Royal Melbourne Hospital in Victoria, Australia, presented long-term data from the Zometa-Femara Adjuvant Synergy Trial (ZO-FAST) trial at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 6-10, 2011.

De Boer and colleagues explored adding zoledronic acid, an intravenous bisphosphonate, to adjuvant endocrine therapy to reduce bone mineral density loss seen with aromatase inhibitors and to improve survival outcomes.

When he presented initial data from ZO-FAST at the 2010 CTRC-AACR San Antonio Breast Cancer Symposium, de Boer indicated that early zoledronic acid resulted in a significantly improved bone mineral density and an improved disease-free survival. At this year's symposium, he reported long-term data and data on the effect of menopausal status at breast cancer diagnosis on disease-free survival.

Researchers randomly assigned 1,065 patients who were about to commence letrozole, an aromatase inhibitor, to receive immediate zoledronic acid every six months or to a delayed group where zoledronic acid was started at a later time only if the patient experienced a fracture or a documented fall in bone mineral density.

After 60 months of follow-up, "the primary endpoint of the trial was successfully achieved -- up-front zoledronic acid significantly decreased bone mineral density loss in both the lumbar spine and the hip," de Boer said. "The secondary endpoint of an improvement in disease-free survival was also met with a 34 percent decrease in disease recurrence in the patients receiving the up-front zoledronic acid."

Researchers conducted an exploratory subgroup analysis based on menopausal status at the time of breast cancer diagnosis. Data indicated that in women who were truly menopausal at diagnosis, immediate treatment with zoledronic acid reduced the risk for disease recurrence by 29 percent and improved overall survival by 35 percent.

"In addition, patients in the delayed group, who did not start with zoledronic acid but who switched to start at a later time, also appeared to benefit from the zoledronic acid with an improvement in disease outcomes compared with those women who never started the bisphosphonate," de Boer said.

Additional studies are needed to fully define the patient populations most likely to benefit from adjuvant zoledronic acid in this setting.

Until then, "patients with hormone receptor-positive breast cancer who are postmenopausal and about to commence letrozole have the option of considering the addition of zoledronic acid -- primarily to maintain bone mineral density but also with the aim of reducing the risk for disease recurrence," de Boer said.
-end-
The mission of the CTRC-AACR San Antonio Breast Cancer Symposium is to produce a unique and comprehensive scientific meeting that encompasses the full spectrum of breast cancer research, facilitating the rapid translation of new knowledge into better care for patients with breast cancer. The Cancer Therapy & Research Center (CTRC) at The University of Texas Health Science Center at San Antonio, the American Association for Cancer Research (AACR) and Baylor College of Medicine are joint sponsors of the San Antonio Breast Cancer Symposium. This collaboration utilizes the clinical strengths of the CTRC and Baylor and the AACR's scientific prestige in basic, translational and clinical cancer research to expedite the delivery of the latest scientific advances to the clinic. The 34th annual symposium is expected to draw nearly 8,000 participants from more than 90 countries.

American Association for Cancer Research

Related Postmenopausal Articles from Brightsurf:

Team sport lowers blood pressure in postmenopausal women
Team sport effectively counteracts diminished vascular function in women with high blood pressure, even several years after the onset of menopause.

Socioeconomics, metabolic syndrome, and osteopenia in postmenopausal women
The increased prevalence of metabolic syndrome and osteoporosis in postmenopausal women has prompted multiple research studies to understand why.

Earlier falls predict subsequent fractures in postmenopausal women
The risk of fracture in postmenopausal women can be predicted by history of falls, according to new findings from the Kuopio Osteoporosis Risk Factor and Prevention Study (OSTPRE) at the University of Eastern Finland.

Sexual trauma common in postmenopausal women veterans
Thanks to increased media attention, sexual assaults occurring in the military are finally getting the attention they deserve.

Web tool prioritizes health risks for postmenopausal women
A new web-based calculator helps middle-aged women predict their risks of experiencing heart attack, stroke, hip fracture, or breast, lung or colorectal cancer within 5, 10 or 15 years.

Pear-shaped is better for postmenopausal women, even if they are normal weight
Postmenopausal women who are 'apple' shaped rather than 'pear' shaped are at greater risk of heart and blood vessel problems, even if they have a normal, healthy body mass index (BMI) according to new research published in the European Heart Journal.

Quitting smoking is associated with reduced risk of bladder cancer in postmenopausal women
A large study of postmenopausal women indicated that quitting cigarette smoking was associated with significantly reduced risk of bladder cancer.

Many postmenopausal women do not receive treatment for osteoporosis
The benefits of treating osteoporosis in postmenopausal women outweigh the perceived risks, according to a Clinical Practice Guideline issued today by the Endocrine Society.

Drug cocktail may treat postmenopausal PCOS complications
A combination of a diabetes drug and a high blood pressure medication may effectively treat all symptoms of postmenopausal polycystic ovary syndrome (PCOS).

How common is endometrial cancer in women with postmenopausal bleeding?
Postmenopausal bleeding is a common symptom among most women with endometrial cancer but most women with postmenopausal bleeding won't be diagnosed with endometrial cancer, findings that raise questions about how to best manage postmenopausal bleeding for the early detection of endometrial cancer.

Read More: Postmenopausal News and Postmenopausal Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.